Literature DB >> 8079066

Drug-induced agranulocytosis treated with granulocyte-macrophage colony stimulating factor.

R Hurtado1, M Candelaria, A Majluf-Cruz, R E Sosa-Camas, J Labardini-Méndez.   

Abstract

Drug induced agranulocytosis (DIA) is a potentially lethal disorder characterized by selective neutropenia. Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been utilized for its treatment. We report four cases of DIA treated with GM-CSF at the dose of 5 micrograms/kg/day. The patients presented infectious diseases at diagnosis. Median days to obtain 1 x 10(9)/L neutrophils and a normal neutrophil count (NNC), were 7(5-9) and 7.5 (6-10) days, respectively. The infectious disease at diagnosis improved and all patients are alive at the moment of this report. No other adverse effects than thrombocytosis (two cases) and thrombocytopenia (one case) were observed. We consider that GM-CSF could be a safe and effective alternative in the treatment of DIA.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8079066

Source DB:  PubMed          Journal:  Rev Invest Clin        ISSN: 0034-8376            Impact factor:   1.451


  2 in total

1.  Severe neutropenia: a diagnostic approach.

Authors:  H G Munshi; R B Montgomery
Journal:  West J Med       Date:  2000-04

2.  Monocytopenia in clozapine-induced agranulocytosis: insights into pathophysiology and treatment.

Authors:  Rajvi Patel; Ateaya Lima; Christopher Burke; Mark Hoffman
Journal:  BMJ Case Rep       Date:  2019-01-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.